PR Newswire/Les Echos/ AbbVie Files a Form 8-K NORTH CHICAGO, Ill., Jan. 2, 2013 -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission ("SEC") on January 2, 2013, announcing the effectiveness of its separation and distribution agreement with Abbott Laboratories. AbbVie is now an independent public company trading under the symbol "ABBV" on the New York Stock Exchange, NYSE Euronext Paris, the Chicago Stock Exchange and the SIX Swiss Exchange. AbbVie also announced in the Form 8-K that on December 31, 2012, the Board of Directors of AbbVie expanded its size from three directors to nine directors, and that AbbVie amended and restated its Certificate of Incorporation and By-laws. AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie's website at www.abbvieinvestor.com. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at http://www.sec.gov. Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investors Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A. SOURCE AbbVie Inc. The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication. -0- Jan/03/2013 08:26 GMT
AbbVie Files a Form 8-K
Press spacebar to pause and continue. Press esc to stop.